Ken Griffin Cumberland Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.39 - $1.78 $19,321 - $24,742	-13,900 Reduced 36.48%	24,200 $37,000
Q1 2024 May 15, 2024	SELL	$1.68 - $2.24 $4,200 - $5,600	-2,500 Reduced 6.16%	38,100 $64,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.14 $13,120 - $17,548	8,200 Added 25.31%	40,600 $72,000
Q3 2023 Nov 14, 2023	BUY	$1.43 - $2.3 $143 - $229	100 Added 0.31%	32,400 $61,000
Q2 2023 Aug 14, 2023	BUY	$1.47 - $2.01 $12,936 - $17,687	8,800 Added 37.45%	32,300 $47,000
Q1 2023 May 15, 2023	BUY	$1.92 - $2.75 $41,280 - $59,125	21,500 Added 1075.0%	23,500 $45,000
Q4 2022 Feb 14, 2023	BUY	$2.11 - $2.6 $4,220 - $5,200	2,000 New	2,000 $4,000

24.2K

200

Ticker CPIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 14,661,900
Market Cap $18.3M
Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.